Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2025 16:05 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that...
March 03, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to showcase expected best-in-class durability ...
February 25, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ to Present at Two Investor Conferences in March

BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that...
February 24, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that...
February 03, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced...
January 17, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina experience, today...
January 14, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024 First wet AMD registrational...
January 08, 2025 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation

Company presentation scheduled on Monday, January 13th at 5:15 PM PT Ocular to provide enrollment update for SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, future opportunities...
December 13, 2024 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the...
December 10, 2024 07:30 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world...